Technology Transfer Connects Researchers and Product Developers
Technologies Available for License
HJF’s office of technology transfer helped victims of traumatic injury by transferring an innovative coagulation technology to an industry partner for clinical adoption.
HJF paved the way for two important therapies that help save the lives of thousands of infants at risk for RSV infection every year. The story of this successful collaboration that produced the FDA-approved drugs RespiGam® and Synagis® began in the 1970s. The result: these drug therapies continue to save the lives of premature infants and fragile young children.
Each year, Respiratory Syncytial Virus (RSV) causes epidemics of severe bronchiolitis and pneumonia in premature infants and fragile children. In 1995, a new preventive therapy was developed through a collaborative effort involving researchers from the Uniformed Services University (USU) and the National Institutes of Health (NIH), and facilitated by HJF.
When Kerala State in India began reporting its first-ever cases of Nipah virus in May 2018, they knew the rare, brain-damaging virus that makes its home in fruit bats had struck the country twice before. Ultimately, the virus killed 17 of the 18 people who became infected in that outbreak. HJF's Technology Transfer worked to provide immediate help with a therapeutic.
If you’re a principal investigator or scientist looking for funding or support for your research, find out what we can do for you.
Let’s partner to advance military medicine.
Join our global team!